The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of circulating tumor DNA (ctDNA) for recurrence detection across solid tumors: A real-world meta-analysis.
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Alentis Therapeutics; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Erasca, Inc; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Iterion Therapeutics; Kivu Biosciences; Marengo Therapeutics; Pfizer; Regeneron; Roche; SageMedic; SERVIER; Shionogi; T-Cypher Bio; Tachyon Therapeutics; Transcode; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Boehringer Ingelheim; EMD Serono; Genentech; Pfizer; Roche; Zentalis
 
George Laliotis
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Maen Abdelrahim
Consulting or Advisory Role - AstraZeneca; Ipsen
 
Midhun Malla
Consulting or Advisory Role - AstraZeneca; BillionToOne; BMS; do moore; Exelixis; Incyte; Ipsen; Natera
Travel, Accommodations, Expenses - ESMO GI
 
Richard Kim
Honoraria - Natera
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Eisai; Elevar Therapeutics; Exelixis; Jazz Pharmaceuticals; Pfizer; Roche/Genentech; SERVIER; Taiho Oncology; Takeda
 
Robert Martin
Consulting or Advisory Role - AngioDynamics
Research Funding - Merck Sharp & Dohme (Inst)
 
Arnab Basu
Honoraria - Cardinal Health; Eisai; Gilead Sciences; Natera
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; Daiichi Sankyo/UCB Japan (I); EMD Serono; Seagen
Research Funding - Astellas Pharma (Inst); AVEO (Inst); Bristol-Myers Squibb/Celgene (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Merck (Inst); Natera (Inst)
 
Aditya Bardia
Consulting or Advisory Role - Alyssum; Daiichi Sankyo/Astra Zeneca; Genentech; Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly; Lilly (Inst); Menarini; Menarini (Inst); Merck; Mersana; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health (Inst); Sanofi
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Luke Jacobsen
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Shruti Sharma
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Michael Toboni
Consulting or Advisory Role - Caris LIfe Sciences
Research Funding - Exelixis; GlaxoSmithKline; Karyopharm Therapeutics
 
Gary Schwartz
No Relationships to Disclose
 
Zeynep Eroglu
Consulting or Advisory Role - Natera; Pfizer; Regeneron; Replimune; Sun Pharma
Research Funding - Boehringer Ingelheim (Inst); Pfizer (Inst)
 
Samuel Klempner
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BeiGene; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; EsoBiotec; Gilead Sciences; I-Mab; Merck; Novartis; Taiho Oncology
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); BeiGene (Inst); I-Mab (Inst); Leap Therapeutics (Inst); Mersana (Inst)
Other Relationship - Clinical Care Options; NCCN; Research to Practice
(OPTIONAL) Uncompensated Relationships - Debbies Dream Foundation
 
Gregory Botta
Stock and Other Ownership Interests - Natera
Honoraria - Merus; Natera
Consulting or Advisory Role - Natera
Speakers' Bureau - Natera
 
Marla Lipsyc-Sharf
Honoraria - Exact Sciences; Natera; Novartis
Consulting or Advisory Role - Exact Sciences; Guardant Health; Lilly; Natera; Novartis; Stemline Therapeutics; Tersera
Speakers' Bureau - Lilly
Research Funding - Bridgebio; Natera; Stemline Therapeutics
Travel, Accommodations, Expenses - Exact Sciences; Lilly; Natera
 
Adham Jurdi
Employment - Natera
Stock and Other Ownership Interests - Agenus; Iovance Biotherapeutics; natera; Verastem
 
Minetta Liu
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Alexey Aleshin
Employment - Alameda Health System (I); Natera
Leadership - Natera
Stock and Other Ownership Interests - Natera
Travel, Accommodations, Expenses - Natera
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792